Gyeonggi-do, South Korea

Min Sun Kim

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 9.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Min Sun Kim: Innovator in Autoimmune Disease Treatment

Introduction

Min Sun Kim is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of autoimmune diseases. With a total of 4 patents to his name, Kim is recognized for his innovative approaches to medical challenges.

Latest Patents

One of Kim's latest patents involves an isolated anti-FcRn antibody. This antibody binds to the neonatal Fc receptor (FcRn), which has a high affinity for immunoglobulin G (IgG) or its fragments. The patent outlines a method for preparing this antibody, as well as a composition for treating autoimmune diseases that includes the antibody. The FcRn-specific antibody binds to FcRn non-competitively with IgG, effectively reducing serum pathogenic auto-antibody levels. This innovative approach holds promise for the treatment and diagnosis of various autoimmune diseases.

Career Highlights

Min Sun Kim is currently associated with Hanall Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the biopharmaceutical industry, focusing on creating effective treatments for complex health issues.

Collaborations

Kim collaborates with notable colleagues, including Sung Wuk Kim and Seung Kook Park. These partnerships enhance the research and development process, fostering innovation in the field.

Conclusion

Min Sun Kim's contributions to the treatment of autoimmune diseases through his innovative patents highlight his role as a leading inventor in the biopharmaceutical sector. His work continues to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…